{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:51Z","timestamp":1793727831702,"version":"4.6.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xcrm.2024.101824","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T10:35:26Z","timestamp":1731407726000},"page":"101824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell\/neuroendocrine bladder and prostate cancers"],"prefix":"10.1016","volume":"5","author":[{"given":"Yiqian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazy","family":"Zomorodian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-9200","authenticated-orcid":false,"given":"Arnold I.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101824_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.24858","article-title":"Should extrapulmonary small cell cancer be managed like small cell lung cancer?","volume":"116","author":"Brennan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101824_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/cncy.21765","article-title":"Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers","volume":"124","author":"Duan","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.xcrm.2024.101824_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JOP.18.00204","article-title":"Managing Patients With Relapsed Small-Cell Lung Cancer","volume":"14","author":"Gong","year":"2018","journal-title":"J.\u00a0Oncol. Pract."},{"key":"10.1016\/j.xcrm.2024.101824_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clgc.2012.11.002","article-title":"A clinical review of small-cell carcinoma of the urinary bladder","volume":"11","author":"Thota","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.xcrm.2024.101824_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J.\u00a0Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.xcrm.2024.101824_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101824_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1073\/pnas.1915770117","article-title":"A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101824_bib9","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1038\/s41388-018-0192-5","article-title":"Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics","volume":"37","author":"Shen","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101824_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0002-9440(10)62369-3","article-title":"Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma","volume":"166","author":"Cheng","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.xcrm.2024.101824_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.seminoncol.2012.08.009","article-title":"Small cell bladder cancer: biology and management","volume":"39","author":"Fahed","year":"2012","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/cam4.577","article-title":"Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma","volume":"5","author":"Geynisman","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2024.101824_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","article-title":"Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center","volume":"64","author":"Lynch","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2024.101824_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib15","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib17","article-title":"Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.xcrm.2024.101824_bib18","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2024.101824_bib19","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib20","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib21","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101824_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2020.10.009","article-title":"Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience","volume":"19","author":"Hoffman-Censits","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.xcrm.2024.101824_bib24","article-title":"Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases","volume":"10","author":"Pokhrel","year":"2022","journal-title":"J.\u00a0Investig. Med. High Impact Case Rep."},{"key":"10.1016\/j.xcrm.2024.101824_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.xcrm.2024.101824_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430336","article-title":"Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons","volume":"44","author":"Liao","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.xcrm.2024.101824_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010109","article-title":"Comparative Analysis of Predictive Biomarkers for PD-1\/PD-L1 Inhibitors in Cancers: Developments and Challenges","volume":"14","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101824_bib28","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101824_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1209243","article-title":"Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers","volume":"11","author":"Mo","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xcrm.2024.101824_bib31","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101824_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-cell repertoire diversity: friend or foe for protective antitumor response?","volume":"41","author":"Porciello","year":"2022","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T\u00a0cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101824_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/2326-6066.CIR-20-0398","article-title":"Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 Therapy","volume":"9","author":"Bortone","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","article-title":"Peripheral T\u00a0cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101824_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4 T\u00a0cells in cancer immunotherapy - new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101824_bib37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T\u00a0cells Mediate anti-tumor Cytotoxicity in Human Bladder Cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101824_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101824_bib39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101824_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101824_bib41","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-21-1200","article-title":"Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy","volume":"27","author":"Casarrubios","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib42","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T\u00a0cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101824_bib43","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.immuni.2023.06.025","article-title":"Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T\u00a0cells and enables cross-species interpretation","volume":"56","author":"Zwijnenburg","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101824_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575175","article-title":"Roles for the FCRL6 Immunoreceptor in Tumor Immunology","volume":"11","author":"Davis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101824_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101824_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101818","article-title":"T cell control of inflammaging","volume":"70","author":"Shchukina","year":"2023","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101824_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MOU.0000000000001013","article-title":"Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder","volume":"32","author":"Laukhtina","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.xcrm.2024.101824_bib48","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/curroncol30040323","article-title":"Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond","volume":"30","author":"Lanka","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.xcrm.2024.101824_bib49","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic Landscape of Neuroendocrine Prostate Cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101824_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108255","article-title":"Current and emerging therapies for neuroendocrine prostate cancer","volume":"238","author":"Alabi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2024.101824_bib51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101824_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.xcrm.2024.101824_bib53","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101824_bib54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101824_bib55","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.immuni.2022.09.002","article-title":"Spatial maps of T\u00a0cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response","volume":"55","author":"Liu","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101824_bib56","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","article-title":"Spatial heterogeneity of the T\u00a0cell receptor repertoire reflects the mutational landscape in lung cancer","volume":"25","author":"Joshi","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101824_bib57","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101824_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101824_bib59","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.xcrm.2024.101824_bib60","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101824_bib61","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101824_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101824_bib63","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1093\/bioinformatics\/btaa611","article-title":"Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing data","volume":"36","author":"Sturm","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101824_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.706907","article-title":"ggVennDiagram: An Intuitive, Easy-to-Use, and Highly Customizable R Package to Generate Venn Diagram","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2024.101824_bib65","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101824_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101824_bib67","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124005950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124005950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:10:10Z","timestamp":1758687010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124005950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666379124005950"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101824","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell\/neuroendocrine bladder and prostate cancers","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101824"}}